CS-3150
PreclinicalSmall molecule
Daiichi SankyoCS-3150 is one of 13 small molecule programs targeting Primary Aldosteronism. It is currently in Preclinical.
1
Indications
11
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Primary Aldosteronism
#DrugCompanyPhaseTrials
1Kerendia
BayerApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Parlodel
VVeroScience
Approved
Baxfendy
AstraZenecaPhase 3
Aldactone
PfizerPreclinical
Adrenocorticotropic Hormone
AstellasPreclinical
Intensive BP Control
SSecond Affiliated Hospital of Nanchang University
Preclinical
Nifedipine ER
MMedical College of Wisconsin
Preclinical
Mineralocorticoid Receptor Antagonists
UUniversity of Pennsylvania
Preclinical
Antihypertensive Medication
UUniversity of Alberta
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension3 trials
Renal Impairment2 trials
Type 2 Diabetes1 trial
3 more indications
Efficacy and Safety1 trial
TED1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS-3150. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company